Matches in SemOpenAlex for { <https://semopenalex.org/work/W2281467231> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2281467231 abstract "Background and Purpose: Several large trials published over the last decade have significantly altered recommended guidelines for therapy following a noncardioembolic ischemic stroke or transient ischemic attack (TIA). We examined utilization patterns of these agents over the last decade, with regards to the publication of the MATCH, ESPRIT, and PRoFESS clinical trials, to study the implementation of the results of such trials in clinical practice. Methods: Antithrombotic utilization was prospectively collected as part of the National Ambulatory Medical Care Survey (NAMCS) between 2000 and 2009. Patients with a history of ischemic stroke or TIA were included with the exception of those with a concomitant history of atrial fibrillation, atrial flutter, or heart valve replacement. Annual utilization prevalence of the following antithrombotic strategies was compared: aspirin monotherapy, clopidogrel monotherapy, combined clopidogrel and aspirin, dipyridamole-aspirin, and warfarin. Average annual prevalence was compared before and after publication of MATCH in 2004, ESPRIT in 2006, and PRoFESS in 2008. A second pre-specified analysis excluded patients with known coronary artery disease (CAD) to censor the use of combined clopidogrel and aspirin for treatment of CAD after the 2001 CURE and 2002 CREDO trials showed a benefit of extended dual antiplatelet therapy. Results: An annual average of 4,221,059 patients between 2000 and 2009 met criteria for evaluation. After the 2004 MATCH trial, the annualized rate of combined clopidogrel and aspirin use increased from 3.3% before trial publication to 6.8% afterwards (p<0.0001). When patients with CAD were excluded an increase of 3.3% to 5.5% was found during the same period (p<0.0001). Following the 2006 ESPRIT trial, the annualized rate of dipyridamole-aspirin use increased from 2.8% to 4.6% (p<0.0001); the annualized rate of clopidogrel use increased from 12.8% to 17.8% (p<0.0001); and the annualized rate of aspirin use increased from 12.6% to 16% (p<0.0001). After the PRoFESS trial, published in late 2008, the annualized rate of clopidogrel use increased from 13.8% to 19% (p<0.0001); the annualized rate of dipyridamole-aspirin use minimally increased from 3.3% to 4% (p<0.0001); and the annualized rate of aspirin use decreased from 14.2% to 11% (p<0.0001). Conclusion: The impact of the MATCH, ESPRIT, and PRoFESS trials on antithrombotic utilization has been variable. The results highlight the importance of addressing factors that facilitate or hinder the implementation of results from such trials into practice." @default.
- W2281467231 created "2016-06-24" @default.
- W2281467231 creator A5020049468 @default.
- W2281467231 creator A5054796414 @default.
- W2281467231 creator A5080447515 @default.
- W2281467231 creator A5085189994 @default.
- W2281467231 date "2012-02-01" @default.
- W2281467231 modified "2023-09-28" @default.
- W2281467231 title "Abstract 3066: Implementation of Results from Major Clinical Trials on Utilization Patterns of Antithrombotic Agents following Noncardioembolic Ischemic Stroke or TIA in the United States (2000-2009)" @default.
- W2281467231 doi "https://doi.org/10.1161/str.43.suppl_1.a3066" @default.
- W2281467231 hasPublicationYear "2012" @default.
- W2281467231 type Work @default.
- W2281467231 sameAs 2281467231 @default.
- W2281467231 citedByCount "0" @default.
- W2281467231 crossrefType "journal-article" @default.
- W2281467231 hasAuthorship W2281467231A5020049468 @default.
- W2281467231 hasAuthorship W2281467231A5054796414 @default.
- W2281467231 hasAuthorship W2281467231A5080447515 @default.
- W2281467231 hasAuthorship W2281467231A5085189994 @default.
- W2281467231 hasConcept C126322002 @default.
- W2281467231 hasConcept C127413603 @default.
- W2281467231 hasConcept C164705383 @default.
- W2281467231 hasConcept C168563851 @default.
- W2281467231 hasConcept C2776301958 @default.
- W2281467231 hasConcept C2776890861 @default.
- W2281467231 hasConcept C2777015399 @default.
- W2281467231 hasConcept C2777628954 @default.
- W2281467231 hasConcept C2777849778 @default.
- W2281467231 hasConcept C2778213512 @default.
- W2281467231 hasConcept C2779161974 @default.
- W2281467231 hasConcept C2780645631 @default.
- W2281467231 hasConcept C535046627 @default.
- W2281467231 hasConcept C71924100 @default.
- W2281467231 hasConcept C78519656 @default.
- W2281467231 hasConceptScore W2281467231C126322002 @default.
- W2281467231 hasConceptScore W2281467231C127413603 @default.
- W2281467231 hasConceptScore W2281467231C164705383 @default.
- W2281467231 hasConceptScore W2281467231C168563851 @default.
- W2281467231 hasConceptScore W2281467231C2776301958 @default.
- W2281467231 hasConceptScore W2281467231C2776890861 @default.
- W2281467231 hasConceptScore W2281467231C2777015399 @default.
- W2281467231 hasConceptScore W2281467231C2777628954 @default.
- W2281467231 hasConceptScore W2281467231C2777849778 @default.
- W2281467231 hasConceptScore W2281467231C2778213512 @default.
- W2281467231 hasConceptScore W2281467231C2779161974 @default.
- W2281467231 hasConceptScore W2281467231C2780645631 @default.
- W2281467231 hasConceptScore W2281467231C535046627 @default.
- W2281467231 hasConceptScore W2281467231C71924100 @default.
- W2281467231 hasConceptScore W2281467231C78519656 @default.
- W2281467231 hasIssue "suppl_1" @default.
- W2281467231 hasLocation W22814672311 @default.
- W2281467231 hasOpenAccess W2281467231 @default.
- W2281467231 hasPrimaryLocation W22814672311 @default.
- W2281467231 hasRelatedWork W1589727351 @default.
- W2281467231 hasRelatedWork W1970967952 @default.
- W2281467231 hasRelatedWork W1992264743 @default.
- W2281467231 hasRelatedWork W2070121222 @default.
- W2281467231 hasRelatedWork W2103774132 @default.
- W2281467231 hasRelatedWork W2108116405 @default.
- W2281467231 hasRelatedWork W2122942100 @default.
- W2281467231 hasRelatedWork W2128193817 @default.
- W2281467231 hasRelatedWork W2151957090 @default.
- W2281467231 hasRelatedWork W2308792962 @default.
- W2281467231 hasRelatedWork W2477288824 @default.
- W2281467231 hasRelatedWork W2810872557 @default.
- W2281467231 hasRelatedWork W2964508099 @default.
- W2281467231 hasRelatedWork W2982308247 @default.
- W2281467231 hasRelatedWork W3005738087 @default.
- W2281467231 hasRelatedWork W3048569015 @default.
- W2281467231 hasRelatedWork W3139199959 @default.
- W2281467231 hasRelatedWork W3161960578 @default.
- W2281467231 hasRelatedWork W3194397706 @default.
- W2281467231 hasRelatedWork W3205723431 @default.
- W2281467231 hasVolume "43" @default.
- W2281467231 isParatext "false" @default.
- W2281467231 isRetracted "false" @default.
- W2281467231 magId "2281467231" @default.
- W2281467231 workType "article" @default.